Recent publications

• Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis December 19, 2025
  CONCLUSIONS: Voriconazole was used nearly twice as frequently as isavuconazole, despite isavuconazole having more predictable pharmacokinetics and a lower propensity for severe drug-drug interactions versus voriconazole. The still-frequent use of isavuconazole may reflect its lower inhibition of CNIs and mTOR inhibitors. Resulting drug-drug interactions may be serious and dose adjustment and therapeutic drug monitoring are […]
  Barbara Alexander
• Continuing as Partners in Immunization: Building Immunization Confidence Through Communication, Education, and Resources December 19, 2025
  Immunizations are among the most effective public health measures, significantly reducing the prevalence of serious infectious diseases across the population. Their success is so profound that many in the United States have never witnessed the devastating effects of illnesses, such as measles, polio, or diphtheria. Despite this progress, the Centers for Disease Control and Prevention […]
  Jennifer E Girotto
• Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy December 11, 2025
  Cancer immunotherapy has emerged as a transformative strategy for treating malignancies by harnessing the body's immune system. However, its clinical efficacy is often limited by the complex and immunosuppressive nature of the tumor microenvironment (TME), which poses substantial barriers to therapeutic success. The TME comprises a variety of components, including immune cells, cancer-associated fibroblasts, abnormal […]
  Bao-Toan Dang
• Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study December 9, 2025
  CONCLUSIONS: These findings inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes.
  Catherine B Johannes
• Methods of identifying transthyretin amyloid cardiomyopathy in secondary data sources: a systematic review December 8, 2025
  CONCLUSIONS: Methods for identifying ATTR-CM in studies of secondary datasets were heterogeneous. Future research should focus on optimizing ATTR-CM identification algorithms and performing validation studies.
  Craig I Coleman
• Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018-2023 November 26, 2025
  Contemporary data on coccidioidomycosis death rates are sparse. Death certificate data for 2018-2023 from the US National Vital Statistics System were evaluated. Coccidioidomycosis deaths were identified using diagnosis codes B38.x listed anywhere on certificates. Deaths and age-adjusted mortality rates (AAMRs)/1,000,000 people, with 95% confidence intervals (CIs), were determined. We identified 1760 coccidioidomycosis-attributable deaths (AAMR = […]
  Huiqiao Fan
• Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data November 24, 2025
  CONCLUSIONS: Among patients with a death certificate with aspergillosis, primary attributable mortality was 22.0%. Our results may be useful as experts seek to better understand the true epidemiology of aspergillosis, develop efforts to raise disease awareness, and reduce aspergillosis-related mortality.
  Thomas J Walsh
• Lutetium Lu 177 vipivotide tetraxetan: A literature review November 11, 2025
  To review pharmacology, pharmacokinetics, therapeutic use, product safety/description and perspectives on use of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). Data sources: A literature search was conducted using PubMed/Dynamed (October 2013-May 2025), limited to English language, humans, clinical trials, case reports, and guidelines. Data summary: Lutetium Lu 177 vipivotide […]
  Grace Morrison
• Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1-Year After Adult Heart Transplant November 11, 2025
  CONCLUSIONS: In a large national database, utilizing novel ML modeling techniques, we identified annual transplant center volume, donor ischemia time, and LVAD use at the time of HT as the best predictors of CS discontinuation 1 year after HT.
  Caroline Chen
• Infrared thermal mapping of osteotomy: influence of drill diameter and implant system October 20, 2025
  CONCLUSION: The study found significant variations in temperature increase based on the implant system and drill diameter. Baseline temperature, pilot drill, and second drill temperatures were significant predictors of the third final drill temperature, while the implant system itself was not a significant factor.
  Daniel Alvitez-Temoche
• Continuing as Partners in Immunization: Updates to Practice and Legislation for Pediatric Pharmacy Immunizations October 20, 2025
  No abstract
  Jennifer E Girotto
• Effectiveness and Safety of Rivaroxaban Versus Warfarin in Venous Thromboembolism Patients with Comorbid Obstructive Sleep Apnea: A Retrospective Cohort Study October 15, 2025
  IntroductionObstructive sleep apnea (OSA) is prevalent in patients with venous thromboembolism (VTE). We sought to evaluate the effectiveness and safety of rivaroxaban versus warfarin in VTE patients with comorbid OSA.MethodsWe performed retrospective cohort analyses using the Optum^(®) de-identified Electronic Health Record data set (Optum^(®) EHR) from November 1, 2011 to June 30, 2023. We included […]
  Craig I Coleman
• Misuse of the unspecified coccidioidomycosis diagnosis code: An audit of electronic health records October 13, 2025
  Widespread use of the 'unspecified coccidioidomycosis' code (B38.9) may negatively impact provider reimbursement and complicate study of disease burden. We sought to determine the frequency of B38.9 use in routine practice and assess how often it could be changed to a more specific code, what code that might be, and reasons for its initial use. […]
  Craig I Coleman
• Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials September 29, 2025
  CONCLUSIONS: Current evidence does not support routine screening and treatment of posttransplant ASB in KTRs.
  Abdullah Tarik Aslan
• Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis September 26, 2025
  Objectives: Invasive aspergillosis (IA) poses significant risks to patients with malignancies or transplantation; however, estimates of burden-of-illness in patients with IA are sparse. We sought to assess in-hospital and outpatient healthcare resource utilization, all-cause treatment costs, and mortality in patients admitted with IA with hematologic or non-hematologic malignancies, bone marrow transplant/hematopoietic cell transplantation (BMT/HCT), or […]
  Thomas J Walsh
• Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective August 27, 2025
  This study aimed to estimate the cost-effectiveness of treating invasive aspergillosis (IA) in patients with limited treatment options with either olorofim or currently available antifungal salvage therapy from a US payer perspective. A hybrid decision tree-Markov model with a one-year time horizon was used to estimate health economic outcomes. The model considered probabilities of treatment […]
  Thomas J Walsh
• The Role of Board-Certified Psychiatric Pharmacists in Substance Use Disorder Care July 28, 2025
  No abstract
  Anuja Vallabh
• Polygenic prediction of body mass index and obesity through the life course and across ancestries July 21, 2025
  Polygenic scores (PGSs) for body mass index (BMI) may guide early prevention and targeted treatment of obesity. Using genetic data from up to 5.1 million people (4.6% African ancestry, 14.4% American ancestry, 8.4% East Asian ancestry, 71.1% European ancestry and 1.5% South Asian ancestry) from the GIANT consortium and 23andMe, Inc., we developed ancestry-specific and […]
  Roelof A J Smit
• Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review July 17, 2025
  CONCLUSIONS: Reports of LDBI in pregnant patients are emerging. While some level of withdrawal appears to be frequent, few studies reported precipitated withdrawal, and findings align with LDBI outcomes seen in nonpregnant patients. It is unknown how selection and/or reporting bias impact findings, and prospective, randomized, controlled trials are needed.
  Kyle A Grenier
• Building Implementation Science Capacity in Academic Pharmacy: Report of the 2020-2021 AACP Research and Graduate Affairs Committee July 17, 2025
  The 2020-2021 American Association of Colleges of Pharmacy (AACP) Research and Graduate Affairs Committee (RGAC) continued the work begun by the 2019-2020 RGAC to increase awareness of and capacity for implementation research to advance practice transformation in academic pharmacy. AACP President Anne Lin charged the RGAC with developing resources and programs for training faculty and […]
  Kimberly B Garza